BridgeBio Pharma, Inc. - Common Stock (NQ:BBIO)

66.54 -1.77 (-2.59%)

Streaming Delayed Price Updated: 4:00 PM EST, Feb 25, 2026 Add to My Watchlist

Price and Volume

Volume	5,438,748
Open	70.50
Bid (Size)	64.15 (100)
Ask (Size)	67.39 (200)
Prev. Close	68.31
Today's Range	63.50 - 71.51
52wk Range	28.32 - 84.94
Shares Outstanding	160,500,999
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

BridgeBio (BBIO) Q4 2025 Earnings Call Transcript ↗

February 24, 2026

BridgeBio (BBIO) Q4 2025 Earnings Call Transcript

Via The Motley Fool

BridgeBio Pharma Inc (NASDAQ:BBIO) Posts Q4 Revenue Beat on Heart Drug Surge, Eyes Multiple 2026 NDA Submissions ↗

February 24, 2026

Via Chartmill

Performance

YTD	-14.9%	-14.9%
1 Month	-14.5%	-14.5%
3 Month	-5.8%	-5.8%
6 Month	+36.2%	+36.2%
1 Year	+83.6%	+83.6%

More News

BridgeBio Reports Fourth Quarter and Full Year 2025 Financial Results and Commercial Updates

February 24, 2026

From BridgeBio Pharma, Inc.

Via GlobeNewswire

BridgeBio to Participate in March Investor Conferences

February 23, 2026

From BridgeBio Pharma, Inc.

Via GlobeNewswire

MoonLake Stock Soars As Biotech Fund Reloads, Takeover Chatter Ignites ↗

February 17, 2026

Via Stocktwits

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

February 17, 2026

From BridgeBio Pharma, Inc.

Via GlobeNewswire

Biotech Exit: $26 Million Arcellx Sale Follows Tepid Stock Performance and Kelonia Competition ↗

February 17, 2026

Via The Motley Fool

Cogent Biosciences Stock Up 346% as Fund Builds $29 Million Stake After November Phase 3 Breakthrough ↗

February 17, 2026

Via The Motley Fool

Fund Discloses $35 Million Biotech Buy Amid Staggering 830% Terns Stock Surge ↗

February 17, 2026

Via The Motley Fool

BridgeBio to Report Fourth Quarter and Full Year 2025 Financial Results and Business Update on February 24, 2026 at 4:30 pm ET

February 17, 2026

From BridgeBio Pharma, Inc.

Via GlobeNewswire

Alnylam Pharmaceuticals (ALNY): The RNAi Pioneer’s 2026 Breakout and the Battle for Cardiovascular Dominance

February 12, 2026

Via Finterra

BBIO Stock Surges 17% Pre-Market Today – What’s Fueling The Rally? ↗

February 12, 2026

Via Stocktwits

BridgeBio Reports Positive Phase 3 Topline Results for Oral Infigratinib with the First Statistically Significant Improvements in Body Proportionality in Achondroplasia

February 12, 2026

From BridgeBio Pharma, Inc.

Via GlobeNewswire

The Sound of Silence: Revolution Medicines Plummets 17% as M&A Hopes Evaporate

February 02, 2026

Via MarketMinute

CORRECTING and REPLACING -- BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

January 27, 2026

From BridgeBio Pharma, Inc.

Via GlobeNewswire

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

January 27, 2026

From BridgeBio Pharma, Inc.

Via GlobeNewswire

BridgeBio Prices Offering of $550 Million Convertible Senior Notes due 2033 to Prefund Repayment of Convertible Senior Notes due 2027

January 16, 2026

From BridgeBio Pharma, Inc.

Via GlobeNewswire

BridgeBio Continues Long Term Debt Management Strategy and Announces Proposed Offering of Convertible Senior Notes due 2033 to Prefund Repayment of Convertible Senior Notes due 2027

January 14, 2026

From BridgeBio Pharma, Inc.

Via GlobeNewswire

BridgeBio Announces Commercial Progress, Program Updates, and 2026 Milestones at the 44th Annual J.P. Morgan Healthcare Conference

January 12, 2026

From BridgeBio Pharma, Inc.

Via GlobeNewswire

BridgeBio to Participate in the J.P. Morgan Healthcare Conference

January 05, 2026

From BridgeBio Pharma, Inc.

Via GlobeNewswire

BioMarin’s $4.8 Billion Amicus Acquisition: A Strategic Pivot to Rare Disease Dominance

January 02, 2026

Via MarketMinute

The RNAi Powerhouse: A Deep Dive into Alnylam Pharmaceuticals’ Path to the S&P 500

January 02, 2026

Via PredictStreet

BridgeBio to Host Achondroplasia Investor Webinar on Friday, January 9th at 8:00 am ET

January 02, 2026

From BridgeBio Pharma, Inc.

Via GlobeNewswire

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

December 22, 2025

From BridgeBio Pharma, Inc.

Via GlobeNewswire

Is Rapport Therapeutics Stock a Buy After Investment Firm Cormorant Raised Its Stake Over $60 Million? ↗

December 22, 2025

Via The Motley Fool

Frequently Asked Questions

Is BridgeBio Pharma, Inc. - Common Stock publicly traded?

Yes, BridgeBio Pharma, Inc. - Common Stock is publicly traded.

What exchange does BridgeBio Pharma, Inc. - Common Stock trade on?

BridgeBio Pharma, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for BridgeBio Pharma, Inc. - Common Stock?

The ticker symbol for BridgeBio Pharma, Inc. - Common Stock is BBIO on the Nasdaq Stock Market

What is the current price of BridgeBio Pharma, Inc. - Common Stock?

The current price of BridgeBio Pharma, Inc. - Common Stock is 66.54

When was BridgeBio Pharma, Inc. - Common Stock last traded?

The last trade of BridgeBio Pharma, Inc. - Common Stock was at 02/25/26 04:00 PM ET

What is the market capitalization of BridgeBio Pharma, Inc. - Common Stock?

The market capitalization of BridgeBio Pharma, Inc. - Common Stock is 10.68B

How many shares of BridgeBio Pharma, Inc. - Common Stock are outstanding?

BridgeBio Pharma, Inc. - Common Stock has 11B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.